Austco Healthcare (AHC) H2 2024 earnings summary

Executive summary

• Achieved record FY24 results with revenue up 39% to $58.2 million and NPAT up 213% to $7.1 million, driven by organic growth and two acquisitions.

• EBITDA rose 126% to $8.1 million, exceeding guidance, with strong operating leverage converting revenue growth into profit.

• Unfilled Contracted Orders reached a record $50.3 million, reflecting robust sales momentum.

Financial highlights

• Revenue increased by $16.2 million year-over-year, with $7.0 million from organic growth and $9.2 million from acquisitions.

• Gross Margin rose 37% to $30.7 million, though margin percentage declined slightly to 52.7% due to lower-margin acquisitions.

• Overhead expenses increased by $4.3 million to $25.0 million, including $2.1 million from acquisitions and $0.5 million in one-off M&A costs.

• Cash on hand at year-end was $13.6 million, up from $4.7 million, supported by $11.3 million in operating cash flow.

Outlook and guidance

• Positioned for continued growth with enhanced sales and marketing, especially in high-growth markets.

• Strategic focus on product innovation, partnerships, and further M&A to drive long-term growth.

• Record order backlog of $50.3 million expected to support future revenue growth.